Bevacizumab: Serious neurological disorders and nasal perforations

Prescrire International

Volumn 16, Issue 89, 2007, Pages 112-

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; IMMUNOSUPPRESSIVE AGENT; VASCULOTROPIN;

ARTICLE; BLINDNESS; CAPILLARY LEAK SYNDROME; CLINICAL TRIAL; COLON CANCER; CONSCIOUSNESS DISORDER; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG INDUCED HEADACHE; DRUG INFORMATION; DRUG MARKETING; DRUG TARGETING; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; LEUKOENCEPHALOPATHY; NEUROLOGIC DISEASE; NEUROTOXICITY; NOSE SEPTUM PERFORATION; PATIENT MONITORING; POSTMARKETING SURVEILLANCE; RISK BENEFIT ANALYSIS; SEIZURE; SIDE EFFECT; TREATMENT DURATION; VISUAL DISORDER; WATER RETENTION; WOUND HEALING IMPAIRMENT;

EID: 85047657981     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. U.S. Food and Drug Administration "Important drug warning regarding Avastin° (bevacizumab)" September 2006. Website http://www.fda.gov accessed 4 October 2006: 2 pages.
2. Glusker P et al. "Reversible posterior leukoencephalopathy syndrome and bevacizumab" N Engl J Med 2006; 354 (9): 980-981.
3. Prescrire Editorial Staff "Bevacizumab" Prescrire Int 2006; 15 (83): 94-97.
4. Genentech "Recruitment to resume in Avastin international phase III trial (Avant) in early-stage colon cancer" 22 May 2006: 3 pages.